{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T03:46:01Z","timestamp":1791776761712,"version":"4.3.4"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100019310","name":"Northwell Health Feinstein Institutes for Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019310","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtha.2026.09.020","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:59:32Z","timestamp":1790006372000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Perioperative management of patients on factor XI or factor XIa inhibitors"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3175-461X","authenticated-orcid":false,"given":"Alex C.","family":"Spyropoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Douketis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.09.020_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.58739","article-title":"Standardized management of direct oral anticoagulants for elective procedures","volume":"8","author":"Spyropoulos","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtha.2026.09.020_bib2","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1161\/CIRCULATIONAHA.117.031457","article-title":"Periprocedural outcomes of direct oral anticoagulants versus warfarin in nonvalvular atrial fibrillation: meta-analysis of phase III trials","volume":"138","author":"Nazha","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2026.09.020_bib3","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jamainternmed.2019.2431","article-title":"Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant","volume":"179","author":"Douketis","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jtha.2026.09.020_bib4","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1016\/j.chest.2022.07.025","article-title":"Perioperative management of antithrombotic therapy: an American college of chest physicians clinical practice guideline","volume":"162","author":"Douketis","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2026.09.020_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.6","article-title":"Venous thrombosis","volume":"1","author":"Wolberg","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jtha.2026.09.020_bib6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/a-1384-3715","article-title":"Factor XI as a target for new anticoagulants","volume":"41","author":"Fredenburgh","year":"2021","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jtha.2026.09.020_bib7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1055\/a-1984-7021","article-title":"A review of FXIa inhibition as a novel target for anticoagulation","volume":"43","author":"Koulas","year":"2023","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jtha.2026.09.020_bib8","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1538-7836.2012.04653.x","article-title":"Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European network of rare bleeding disorders","volume":"10","author":"Peyvandi","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.09.020_bib9","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1182\/bloodadvances.2022008648","article-title":"Obstetric and perioperative management of patients with factor XI deficiency: a retrospective observational study","volume":"7","author":"Handa","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2026.09.020_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-222434","article-title":"Successful perioperative management in a patient with factor XI deficiency","volume":"2018","author":"McCarthy","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jtha.2026.09.020_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.17245\/jdapm.2015.15.1.25","article-title":"Factor XI deficiency and orthognathic surgery: a case report on anesthesia management","volume":"15","author":"Lee","year":"2015","journal-title":"J Dent Anesth Pain Med"},{"key":"10.1016\/j.jtha.2026.09.020_bib12","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/17474086.2020.1772745","article-title":"The clinical management of factor XI deficiency in pregnant women","volume":"13","author":"Wheeler","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jtha.2026.09.020_bib13","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3390\/jcdd9040118","article-title":"A case report of severe factor XI deficiency during cardiac surgery: less can be more","volume":"9","author":"Kazui","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1016\/j.jtha.2026.09.020_bib14","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/hae.12655","article-title":"Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study","volume":"21","author":"Bauduer","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.09.020_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.102860","article-title":"Management of bleeding and invasive procedures in patients treated with anti-factor XI(a) anticoagulants: proposals from the french working group on perioperative haemostasis and french society of thrombosis and haemostasis","volume":"9","author":"Godier","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.09.020_bib16","article-title":"Perioperative management of patients receiving factor XI inhibitors","author":"Cheung","year":"2026","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.09.020_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102600","article-title":"The anticoagulant effects of milvexian, a novel small molecule factor XIa inhibitor, are neutralized by activated prothrombin complex concentrates and recombinant factor VIIa in human plasma and whole blood in vitro","volume":"8","author":"Bunce","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.09.020_bib18","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s40262-024-01435-7","article-title":"Effect of age, sex, renal impairment and hepatic impairment on the safety, pharmacokinetics and pharmacodynamics of asundexian","volume":"63","author":"Brase","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtha.2026.09.020_bib19","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s40262-022-01150-1","article-title":"Single-dose pharmacokinetics of milvexian in participants with normal renal function and participants with moderate or severe renal impairment","volume":"61","author":"Perera","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtha.2026.09.020_bib20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.09.020_bib21","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.09.020_bib22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2026.09.020_bib23","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/S0140-6736(25)02097-5","article-title":"Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials","volume":"406","author":"Weitz","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2026.09.020_bib24","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.09.020_bib25","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1111\/jth.15890","article-title":"Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery\u2014systematic review and meta-analysis","volume":"20","author":"Presume","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.09.020_bib26","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/j.jacc.2025.04.018","article-title":"Long-acting factor XI inhibition and periprocedural bleeding","volume":"85","author":"Patel","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2026.09.020_bib27","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41591-023-02794-7","article-title":"Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial","volume":"30","author":"Weitz","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2026.09.020_bib28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.kint.2024.02.024","article-title":"A phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis","volume":"106","author":"Winkelmayer","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.jtha.2026.09.020_bib29","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ekir.2021.11.011","article-title":"Phase 2 study of the factor XI antisense inhibitor IONIS-FXIRx in patients with ESRD","volume":"7","author":"Walsh","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jtha.2026.09.020_bib30","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/ATVBAHA.123.319692","article-title":"Factor XI inhibition for the prevention of catheter-associated thrombosis in patients with cancer undergoing central line placement: a phase 2 clinical trial","volume":"44","author":"Pfeffer","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2026.09.020_bib31","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2516.2004.00944.x","article-title":"The rare coagulation disorders\u2014review with guidelines for management from the United Kingdom haemophilia centre doctors\u2019 organisation","volume":"10","author":"Bolton-Maggs","year":"2004","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.09.020_bib32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1055\/s-0035-1569068","article-title":"The judicious use of recombinant factor VIIa","volume":"42","author":"Goodnough","year":"2016","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2026.09.020_bib33","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.jacc.2025.04.026","article-title":"Perioperative management of patients taking factor XI inhibitors","volume":"85","author":"Douketis","year":"2025","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626006082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626006082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T03:12:02Z","timestamp":1791774722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626006082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":33,"alternative-id":["S1538783626006082"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.09.020","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perioperative management of patients on factor XI or factor XIa inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}